New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
06:01 EDTXOMAXOMA weakness a buying opportunity, says Piper Jaffray
Piper Jaffray recommends buying shares of XOMA on weakness after the company announced that the 6-month Phase II data of gevokizumab in Erosive Osteoarthritis of the Hand failed to support further development. Piper said it had no value of this indication in its $9 price target and reiterates an Overweight rating on the name.
News For XOMA From The Last 14 Days
Check below for free stories on XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XOMA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use